Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Beatrice, Mantoan"'
Autor:
Francesco Cuccia, Rosario Mazzola, Luca Nicosia, Vanessa Figlia, Niccolò Giaj-Levra, Francesco Ricchetti, Michele Rigo, Claudio Vitale, Beatrice Mantoan, Antonio De Simone, Gianluisa Sicignano, Ruggero Ruggieri, Stefano Cavalleri, Filippo Alongi
Publikováno v:
Radiation Oncology, Vol 15, Iss 1, Pp 1-9 (2020)
Abstract Background The assessment of organ motion is a crucial feature for prostate stereotactic body radiotherapy (SBRT). Rectal spacer may represent a helpful device in order to outdistance rectal wall from clinical target, but its impact on organ
Externí odkaz:
https://doaj.org/article/e29eb09b75974456b2945a7e0d418aca
Publikováno v:
Journal of Oncology Pharmacy Practice. 29:457-464
The introduction of inhibitors of poly-(ADP-ribose) polymerase (PARP) for the treatment of women with epithelial ovarian cancers (EOC) has radically changed the treatment in maintenance setting after responding to first- and second-line chemotherapy.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::019a26887648f9e6b3df92acd1f91a0a
https://doi.org/10.1177/10781552221137705
https://doi.org/10.1177/10781552221137705
Autor:
Luca Nicosia, Filippo Alongi, Silvia Andreani, Ruggero Ruggieri, Borislav Rusev, Beatrice Mantoan, Rita Teresa Lawlor, Antonio Pea, Aldo Scarpa, Linda Agolli, Vincenzo Corbo, Sabrina D’Agosto
Publikováno v:
Biomedicines, Vol 8, Iss 12, p 609 (2020)
Pancreatic ductal adenocarcinoma (PDAC) is highly refractory to systemic treatment, including radiotherapy (RT) either as alone or in combination with chemotherapy. Magnetic resonance (MR)-guided RT is a novel treatment technique which conjugates the
Externí odkaz:
https://doaj.org/article/e87510d738eb4c9986b946bd20bd8e7d
Publikováno v:
Journal of Oncology Pharmacy Practice. 28:199-202
Recently, the introduction of encorafenib in combination with cetuximab was considered as a practice changing in BRAFV600-mutated metastatic colorectal cancer. The aim of this paper was to assess the cost-effectiveness of encorafenib plus cetuximab i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fdc98be10f4acb5f747ca1e9db6ac52b
https://doi.org/10.1177/10781552211045006
https://doi.org/10.1177/10781552211045006
Publikováno v:
European journal of cancer (Oxford, England : 1990). 175
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e7a8a2bba205f1e0a238d70cb37210c2
https://pubmed.ncbi.nlm.nih.gov/36137394
https://pubmed.ncbi.nlm.nih.gov/36137394
Publikováno v:
Recenti progressi in medicina. 113(6)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::2ebee30378582378ae8912b77bec2e24
https://pubmed.ncbi.nlm.nih.gov/35758118
https://pubmed.ncbi.nlm.nih.gov/35758118
Publikováno v:
Recenti progressi in medicina. 113(6)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::0d1dd1e4cb2e5f667731c9f75036d5dd
https://pubmed.ncbi.nlm.nih.gov/35758117
https://pubmed.ncbi.nlm.nih.gov/35758117
Autor:
Jacopo Giuliani, Marta Mandara, Beatrice Mantoan, Lucrezia Ferrario, Daniela Mangiola, Giuseppe Napoli, Marco Muraro, Francesco Fiorica
Publikováno v:
Journal of Oncology Pharmacy Practice. :107815522311598
The aim of this paper was to assess the cost-effectiveness of pembrolizumab in first-line for microsatellite-instability-high or mismatch-repair-deficient metastatic colorectal cancer. We have considered the pivotal phase III randomized controlled tr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::376fd6cfe10fa2dbe89994091b27094b
https://doi.org/10.1177/10781552231159844
https://doi.org/10.1177/10781552231159844
Publikováno v:
Recenti progressi in medicina. 112(12)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::471596906f4f955b78ed953460673db3
https://pubmed.ncbi.nlm.nih.gov/34924575
https://pubmed.ncbi.nlm.nih.gov/34924575
Publikováno v:
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners. 28(2)
The introduction of targeted agents (lenvatinib) and immune-based therapies (atezolizumab in combination with bevacizumab) for first-line advanced hepatocellular carcinoma provided new therapeutic options. The aim of this paper was to assess the cost
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b3a19f35b1448571d62e483291fc8bc6
https://pubmed.ncbi.nlm.nih.gov/34581219
https://pubmed.ncbi.nlm.nih.gov/34581219